FAB-GT biopsy data: 100% reduction of kidney substrate at 12 months in first patient dosed with plato ® gene therapy platform Gb3 is a fatty substrate that accumulates in the cells of Fabry disease ...
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying ...
SAN FRANCISCO & SHANGHAI--(BUSINESS WIRE)--AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback